TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03527732

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albendazole
Description: Monotherapy of albendazole (400 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole and Ivermectin
Description: Combination therapy of albendazole (400 mg) and ivermectin (200 µg/kg)
Study: NCT03032978

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: Pulp capping material

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcium silicate
Description: Pulp capping material
Study: NCT04609176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus Apatinib and SOX
Description: Camrelizumab 200mg, day1; Apatinib 250mg qd p.o.;Oxaliplatin 130 mg/m2 day1; S-1 40-60 mg (calculated according to the body surface area) bid day1-14. 3 weeks for one cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus Apatinib
Description: Camrelizumab 200mg, day1; Apatinib 250mg qd p.o. 3 weeks for one cycle.
Study: NCT03599089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: single-dose wound infiltration prior to surgical incision closure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: single-dose wound infiltration prior to surgical incision closure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008
Description: single-dose wound infiltration prior to surgical incision closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-dose wound infiltration prior to surgical incision closure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: 30mg IV administered intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: 30mg IV administered intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: 30mg IV administered intraoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: 30mg IV administered intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000mg IV administered intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000mg IV administered intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000mg IV administered intraoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: 1000mg IV administered intraoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5mg PO prn post-surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5mg PO prn post-surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: 5mg PO prn post-surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 5mg PO prn post-surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.5% infiltration pre-surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.5% infiltration pre-surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.5% infiltration pre-surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.5% infiltration pre-surgery
Study: NCT00624182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine for URLC10
Description: Increasing the doses of URLC10 peptides will be administered by subcutaneous injection on day 1, 8, 15, and 22 of each 28-day treatment cycles. Doses of 0.5, 1.0, 2.0mg/body are planned. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, and 15. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
Study: NCT01885130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil Daily Advance Ultra Hydrating Lotion
Description: 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
Study: NCT02903329

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Detoxification
Description: Two ways of composing the detoxification protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Detoxification
Description: Two ways of composing the detoxification protocol
Study: NCT02283827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Study: NCT02193503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Treatment is the implantation of loaded capsules + injection of irradiated autologous tumor cells
Study: NCT03941288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol
Description: Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued.
Study: NCT00399906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-582949
Description: Tablets, Oral, Once daily, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-582949
Description: Tablets, Oral, Once daily, 12 weeks
Study: NCT01808300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg, Thioctic acid 600mg
Description: * A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~* B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~* C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B
Study: NCT03294031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Warm-up exercises included Abdominal and costal breathing and Pelvic Clock. Some exercises included in the main part of the mat session were Arm arcs, Curls up, Femur arcs, Shoulder bridge, Leg circles, among others. The main part of the sitting/standing session included in standing position exercises like Standing on one leg with support, Neck rolls, Side leg lift with support and in sitting position Spine stretch 5, Elbows back with hands behind his head, Heel/knee slides, Shoulder drops, Knee folds, among others. In mat sessions, cooling exercises included in standing position Hamstring stretch and Abdominal Breathing and Rest position and in sitting/standing session Stretching and Abdominal Breathing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise
Description: All sessions started with a 15-minute warm-up phase based on walking performance and joint mobility exercises. It was followed by a 35-minute second phase, which included low-impact aerobics (music tempo was set at 120 beats per minute), gross motor coordination tasks and balance activities. The final 5-minute phase focused on gentle stretching exercises.
Study: NCT03312959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperbaric bupvacaine in Peribulbar block
Description: hyperbaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isobaric bupvacaine in Peribulbar block
Description: isobaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
Study: NCT00805480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 was administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 was administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 was administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to AIN457 was administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to AIN457 was administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AIN457 was administered intravenously.
Study: NCT01007578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon catheter angioplasty
Description: Paclitaxel-coated balloon catheters for the treatment of peripheral arterial occlusive disease (POAD) of the femoro-popliteal arteries
Study: NCT04793178

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Reserve Index, Masimo Corporation, USA.
Description: The oxygen reserve index (ORI) is a new feature of multiple wavelength pulse oximetry that provides real-time visibility to oxygenation status in the moderate hyperoxic range (PaO2 of approximately 100-200 mm Hg).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index, Masimo Corporation, USA.
Description: The oxygen reserve index (ORI) is a new feature of multiple wavelength pulse oximetry that provides real-time visibility to oxygenation status in the moderate hyperoxic range (PaO2 of approximately 100-200 mm Hg).
Study: NCT01327157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: occlusal adjustment.
Description: It prompted the patient to perform the act of swallowing for 3 times to reach a terminal axis of rotation of the jaw and from this to start. Will be held palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth. After starts the adjustment following the rules of Guichet with a cylindrical drill with a thin cut . basic principles 1 Occlusive stress maximum distribution in centric relation 2 The occlusive strengths should by the teeth's major axis.3 When the contact is surface to surface, it must be exchanged to another surface point. 4 Once the stability to the centric relation is achieved, it should be kept. The rules to guide the occlusal adjustment selective grinding .

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual analog scale.
Description: Visual analog scale-Graduation was held on the visual analogue scale in the first and last query to measure discomfort chewing.Graduation was held on the visual analogue scale .in the first and last query to measure discomfort chewing. After graduating dental cleaning was performed, with the purpose of blinding the study, Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.~Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Visual analog scale.
Description: Visual analog scale-Graduation was held on the visual analogue scale in the first and last query to measure discomfort chewing.Graduation was held on the visual analogue scale .in the first and last query to measure discomfort chewing. After graduating dental cleaning was performed, with the purpose of blinding the study, Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.~Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.
Study: NCT02201407

Intervention type: DRUG
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics and in line with the local labeling.
Study: NCT04538027

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Microdiscectomy at 6 weeks of symptoms
Description: Microscope assisted lumbar discectomy done at 6 weeks of starting symptoms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Microdiscectomy at 3 months of symptoms
Description: Microscope assisted lumbar discectomy done at 3 months of starting symptoms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Microdiscectomy at 6 months of symptoms
Description: Microscope assisted lumbar discectomy done at 6 months of starting symptoms
Study: NCT02295527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based physical exercise intervention
Description: Progressive strengthening of muscle groups ankle dorsi flexors, knee extensors and hip abductors and progressive balance training according to individual capacity:weight-bearing, limits of stability, change of position/direction, maintenance of static and dynamic stability, anticipatory adjustments using different bases of support and different sensory conditions. Dynamic exercises involving spin on its own axis, sitting and standing, up and down stairs, functional reach, steps in different directions and walk training. In the first session the physiotherapist will choose two exercises that best address the participant function goals and will add more exercises each week according to the level of participants' ability and motivation. Participants will receive a detailed booklet, containing photos and instructions of the12 exercises.Visits to follow up exercises will be conducted by the physiotherapists to progress the exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group Usual Care
Description: This group will receive usual care and will not have any disadvantage in participating in the study. We understand that usual care is what participant receives based on the network of health care in which he/she is inserted. The participants will receive at baseline assessment a diary falls logbook and a guidance booklet containing information about prevention of falls, fractures and bone health that will be explained at the moment.
Study: NCT03156088

Intervention type: DEVICE
Intervention: Sacral Neuromodulator InterStim
Study: NCT00399906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-582949
Description: Tablets, Oral, Once daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, Once daily, 12 weeks
Study: NCT03238430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal morphine
Description: A single intrathecal injection of 300 micrograms of Morphine preoperatively, just before induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine PCA
Description: a postoperative Morphine PCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine PCA
Description: a postoperative Morphine PCA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine PCA
Description: a postoperative Morphine PCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine infiltration
Description: Ropivacaine 2mg / ml at the rate of 8ml per hour via a multiperforated catheter with connector after bolus of 20 ml
Study: NCT01254422

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
Description: 0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: NaCl 0.9%
Description: 0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
Study: NCT01036048

Intervention type: DEVICE
Intervention: drug eluting stent
Description: pts with cabg disease treated with drug eluting stent

Intervention type: DEVICE
Intervention: bare metal stent
Description: pts with cabg disease treated with bare metal stent
Study: NCT04587661

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: off-the-shelf digital CBT
Description: Cognitive behavioral therapy for depression and anxiety

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adapted digital CBT
Description: Cognitive behavioral therapy for depression and anxiety for individuals from a minority group with SCD
Study: NCT00847210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 7 days.
Study: NCT03005158

Intervention type: OTHER
Group type: OTHER
Intervention: Validation Phase
Description: Standard care across all sites during the validation phase will rule out myocardial infarction in those with presentation troponin below the 99th centile with greater than 6 hours of symptoms at the time of blood sampling. In those with less than 6 hours of symptoms, a second test will be measured 6- 12 hours after presentation.

Intervention type: OTHER
Group type: OTHER
Intervention: Randomization Phase
Description: Standard care or HighSTEACS pathway.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Phase
Description: Implementation of the HighSTEACS pathway to rule out myocardial infarction in patients with suspected acute coronary syndrome. Myocardial infarction will be ruled out if presentation cardiac troponin concentrations are \<5 ng/L in those with at least 2 hours of symptoms at the time of blood sampling. In patients with less than two hours of symptoms, or where cardiac troponin concentrations are between 5ng/L and the 99th centile, repeat testing will be recommended at 3 hours. Myocardial infarction will be ruled out at 3 hours if cardiac troponin concentrations are unchanged (\<3 ng/L change) and remain ≤99th centile on retesting. Those remaining ≤99th centile on retesting but demonstrating a significant change will require admission for further testing at 6-12 hours.
Study: NCT03798769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Oncology Care at Home
Description: Entails the following:~1. patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers to phone calls and home visits by Medically Home based on a clinician-derived algorithm;~2. scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;~3. regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care.
Study: NCT00867672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPA
Description: VPA starting on day 6 of first cycle continuously throughout all treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPA
Description: VPA starting on day 6 of first cycle continuously throughout all treatment cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Description: ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
Study: NCT00903188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Cyclosporine (Group 1):~basiliximab dose: 1x20 mg IV on Day 0 and 1x20 mg IV on Day 4~Cyclosporine: 8 mg/kg PO given before surgery, followed by 2x4 mg/kg/d. C-0h levels: month 1: 150-250 ng/ml; month 2: 100-200 ng/ml; month 3: withdrawal steroids: 100-150 ng/ml.~C-2h levels: month 1: 900-1100 ng/ml; month 2: 800-1000 ng/ml; month 3: withdrawal steroids: maintain level of 750 ng/ml~Enteric-coated mycophenolate(MPA):720mg PO pre-operatively followed by 1.44 g/day.~Steroids: pre-operatively: 250mg methylprednisolone IV; day 1:125mg IV.~Methylprednisolone:day 2-30:PO 12mg/d; day 31-60:tapered to 8mg/d ,day 61-90 :4mg/d; Month 3:stop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus (Group 2):~Basiliximab dose: idem as in group 1~Cyclosporine: first three months idem group 1; month 3: decreased dose by 50%, simultaneously initiate everolimus at a starting dose of 0.75 mg bid.~Once the everolimus blood levels range 6 - 12 ng/ml, cyclosporine will be stopped.~Enteric-coated mycophenolate (MPA) dosing idem as group 1.~Everolimus starting dose: 0.75 mg bid, trough levels: 6-12 ng/ml.~Steroid dosing: idem group 1, but maintained at 4 mg methylprednisolone after day 60.
Study: NCT03846206

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mediterranean diet
Description: a Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months